Eli Lilly’s $3.2B acquisition of Morphic put renewed focus on Integrin α4β7 as a target in IBD. In collaboration with Sleuth, we assessed the competitive landscape and key risks for MORF-057—including its differentiation potential as a gut-selective oral therapy.
Pharma growth depends on smarter BD decisions. This article outlines a clear framework to evaluate external opportunities before committing to formal diligence.
AI is already transforming how leading organizations identify, evaluate, and close deals, but not all AI platforms are built for BD&L.
Facing a flood of biopharma assets? Learn how AI can help your BD team cut through the noise, gain confidence, and act with purpose.
By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.
Artificial intelligence-powered pipeline analysis is emerging as a tool that can help teams make better, faster drug development decisions.
Implementing guardrails for artificial intelligence (AI) in biopharma is crucial for ensuring effective, safe, and compliant use of this powerful technology.
In biopharma, pipeline analysis provides comprehensive insights into the lifecycle of drug candidates, from discovery through clinical trials to market launch.
Vibe Bio is doing extraordinary work to change drug development: from funding next-generation therapies to helping others identify the highest potential cures.
Insilico Medicine’s mission is to extend healthy, productive longevity by transforming drug discovery and development with generative artificial intelligence.